Transcriptomic differences in MSA clinical variants

dc.contributor.authorPérez Soriano, Alexandra
dc.contributor.authorArnal, Magdalena
dc.contributor.authorBotta Orfila, Teresa
dc.contributor.authorGiraldo, Darly M.
dc.contributor.authorFernández, Manel
dc.contributor.authorCompta, Yaroslau
dc.contributor.authorFernández Santiago, Rubén
dc.contributor.authorEzquerra Trabalón, Mario
dc.contributor.authorTartaglia, Gian Gaetano
dc.contributor.authorMartí, M J
dc.contributor.authorMuñoz García, José Esteban
dc.date.accessioned2022-06-21T14:25:55Z
dc.date.available2022-06-21T14:25:55Z
dc.date.issued2020-06-25
dc.date.updated2022-06-21T14:25:55Z
dc.description.abstractBackground: Multiple system atrophy (MSA) is a rare oligodendroglial synucleinopathy of unknown etiopathogenesis including two major clinical variants with predominant parkinsonism (MSA-P) or cerebellar dysfunction (MSA-C). Objective: To identify novel disease mechanisms we performed a blood transcriptomic study investigating differential gene expression changes and biological process alterations in MSA and its clinical subtypes. Methods: We compared the transcriptome from rigorously gender and age-balanced groups of 10 probable MSA-P, 10 probable MSA-C cases, 10 controls from the Catalan MSA Registry (CMSAR), and 10 Parkinson Disease (PD) patients. Results: Gene set enrichment analyses showed prominent positive enrichment in processes related to immunity and inflammation in all groups, and a negative enrichment in cell differentiation and development of the nervous system in both MSA-P and PD, in contrast to protein translation and processing in MSA-C. Gene set enrichment analysis using expression patterns in different brain regions as a reference also showed distinct results between the different synucleinopathies. Conclusions: In line with the two major phenotypes described in the clinic, our data suggest that gene expression and biological processes might be differentially affected in MSA-P and MSA-C. Future studies using larger sample sizes are warranted to confirm these results.
dc.format.extent9 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec712653
dc.identifier.issn2045-2322
dc.identifier.pmid32587362
dc.identifier.urihttps://hdl.handle.net/2445/186868
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/s41598-020-66221-4
dc.relation.ispartofScientific Reports, 2020, vol. 10, num. 1, p. 10310
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/309545/EU//RIBOMYLOME
dc.relation.urihttps://doi.org/10.1038/s41598-020-66221-4
dc.rightscc-by (c) Pérez Soriano, Alexandra et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationCerebel
dc.subject.classificationMalaltia de Parkinson
dc.subject.classificationDiagnòstic diferencial
dc.subject.classificationExpressió gènica
dc.subject.otherCerebellum
dc.subject.otherParkinson's disease
dc.subject.otherDifferential diagnosis
dc.subject.otherGene expression
dc.titleTranscriptomic differences in MSA clinical variants
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
712653.pdf
Mida:
2.27 MB
Format:
Adobe Portable Document Format